235 related articles for article (PubMed ID: 8564916)
1. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
Shriqui CL
Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
[TBL] [Abstract][Full Text] [Related]
2. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
McGrath JJ; Soares KV
Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
[TBL] [Abstract][Full Text] [Related]
3. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
Soares-Weiser K; Rathbone J
Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
[TBL] [Abstract][Full Text] [Related]
4. Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects.
Tugg LA; Desai D; Prendergast P; Remington G; Reed K; Zipursky RB
Schizophr Res; 1997 May; 25(1):71-8. PubMed ID: 9176929
[TBL] [Abstract][Full Text] [Related]
5. Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics.
Gagné MA; Cormier H; Leblanc G; Lévesque D; Di Paolo T
Can J Psychiatry; 1993 Oct; 38(8):534-40. PubMed ID: 7902199
[TBL] [Abstract][Full Text] [Related]
6. [The "neuroleptic threshold"--a review of the literature].
Abraham D; Kissling W; Lauter H
Psychiatr Prax; 1996 May; 23(3):109-16. PubMed ID: 8710999
[TBL] [Abstract][Full Text] [Related]
7. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
Leblanc G; Cormier H; Gagné MA; Vaillancourt S
Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic medication: clinical guidelines for maintenance therapy.
Johnson DA
J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
[TBL] [Abstract][Full Text] [Related]
9. Drug treatment of schizophrenia. Overview of recent research.
Marder SR; Wirshing WC; Van Putten T
Schizophr Res; 1991; 4(2):81-90. PubMed ID: 1674883
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of schizophrenia in Germany.
Bartels M
Keio J Med; 1992 Jun; 41(2):59-63. PubMed ID: 1352365
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole: new drug. Just another neuroleptic.
Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
[TBL] [Abstract][Full Text] [Related]
13. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
Kane JM
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
[TBL] [Abstract][Full Text] [Related]
14. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
15. Algorithm for treatment-refractory schizophrenia.
Koshino Y
Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S9-13. PubMed ID: 10560891
[TBL] [Abstract][Full Text] [Related]
16. The role of dosage and plasma levels in neuroleptic relapse prevention.
Marder SR
Acta Psychiatr Scand Suppl; 1994; 382():25-7. PubMed ID: 7916525
[TBL] [Abstract][Full Text] [Related]
17. Large variations of plasma levels during maintenance treatment with depot neuroleptics.
Tuninger E; Levander S
Br J Psychiatry; 1996 Nov; 169(5):618-21. PubMed ID: 8932892
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
[TBL] [Abstract][Full Text] [Related]
19. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
[TBL] [Abstract][Full Text] [Related]
20. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
